SCHEMBL6038503

SCHEMBL6038503

CCCc1ccc(S(=O)(=O)Nc2nccnc2OCc2ccccn2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
ATM Q13315 1/20 0.47
ALDH1A1 P00352 3/20 0.44
LMNA P02545 2/20 0.44
HTT P42858 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
FFAR4 Q5NUL3 1/20 0.42
POLB P06746 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
GAA P10253 2/20 0.40
CCR2 P41597 1/20 0.40
ADAMTS4 O75173 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038732 0.91 KMT2A (0.48) MEN1KMT2AATMALDH1A1LMNA
SCHEMBL6038494 0.86 KMT2A (0.50) MEN1KMT2AALDH1A1LMNAL3MBTL1
SCHEMBL6038514 0.86 KDM4E (0.57) MEN1KMT2AATMALDH1A1LMNA
SCHEMBL6038356 0.84 MEN1 (0.46) MEN1KMT2AALDH1A1HTTL3MBTL1
SCHEMBL6039048 0.83 MEN1 (0.49) MEN1KMT2AALDH1A1LMNAHTT
SCHEMBL6038452 0.81 MEN1 (0.46) MEN1KMT2AALDH1A1LMNAHTT
SCHEMBL6039424 0.77 KDM4E (0.60) MEN1KMT2AALDH1A1LMNAL3MBTL1
SCHEMBL6038505 0.77 PTGDR2 (0.50) MEN1KMT2AALDH1A1LMNAHTT
SCHEMBL6039454 0.77 KMT2A (0.47) MEN1KMT2AALDH1A1LMNAL3MBTL1
SCHEMBL6039027 0.77 MEN1 (0.44) MEN1KMT2AALDH1A1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 MEN1 2431/4885KMT2A 4190/4885ATM 1681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.